Ildong Pharmaceutical Presents Research Results on Diabetes Treatment Candidate Substance Poster at ADA

Ildong Pharmaceutical Headquarters Exterior (Photo by Ildong Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] Ildong Pharmaceutical announced on the 28th that it presented research results on the type 2 diabetes treatment candidate substance 'IDG16177' in a poster session at the American Diabetes Association (ADA) conference.

IDG16177 is a GPR40 agonist candidate drug that activates the G protein-coupled receptor 40 (GPR40) of pancreatic beta cells to induce insulin secretion and regulate blood glucose levels.

?

Ildong Pharmaceutical mainly emphasized the comparative study results with the previously discontinued similar candidate substance 'fasiglifam' due to liver toxicity issues. According to Ildong Pharmaceutical, non-clinical test results showed that IDG16177 exhibited superior activity compared to fasiglifam in in vitro experiments and induced insulin secretion at concentrations 100 times lower than fasiglifam.

Additionally, animal experiments demonstrated excellent pharmacokinetic (PK) drug absorption, and in multiple animal models, IDG16177 showed relatively superior blood glucose control ability at doses 30 times lower than fasiglifam. Furthermore, Ildong Pharmaceutical emphasized that drug-induced liver injury (DILI) was significantly reduced.

Ildong Pharmaceutical recently requested approval for the clinical trial plan of IDG16177 from the German Federal Institute for Drugs and Medical Devices (BfArM). Upon approval, Ildong Pharmaceutical plans to initiate Phase 1 clinical trials in Germany.

An Ildong Pharmaceutical official stated, “We have confirmed the efficacy such as blood glucose lowering and safety aspects including toxicity issues through non-clinical results related to IDG16177,” and added, “We plan to promptly start Phase 1 clinical trials as soon as the clinical trial plan is approved.”

This content was produced with the assistance of AI translation services.